Patents Examined by Marcela M. Cordero Garcia
  • Patent number: 10324082
    Abstract: Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 18, 2019
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Stephen W. Taylor, Michael McPhaul, Richard E. Reitz, Zhaohui Chen, Nigel Clarke
  • Patent number: 10322161
    Abstract: The present specification discloses APY cyclic peptides having EphA4 antagonistic activity, pharmaceutical compositions containing such EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in an individual using such APY cyclic peptides or pharmaceutical compositions.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 18, 2019
    Assignees: Sanford Burnham Prebys Medical Discovery Institute, The Scripps Research Institute
    Inventors: Elena B. Pasquale, Philip Dawson, Erika Olson, Stefan J. Riedl
  • Patent number: 10293019
    Abstract: An object of the present invention is to provide a novel treatment method with fewer side effects for elderly cancer patients and terminal cancer patients. A pharmaceutical composition for treating or putting an elderly or a terminal cancer patient into remission, comprising, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 21, 2019
    Assignee: DELTA-FLY PHARMA, INC.
    Inventor: Hiromi Wada
  • Patent number: 10294273
    Abstract: Methods and compositions are provided for generating macrocyclic peptides constrained by side-chain-to-C-terminus non-peptidic tethers for use as functional and structural mimics of ?-helical motifs, including in therapeutic applications. These methods can be used to produce libraries of conformationally constrained peptidomimetics to identify compounds with desired activity properties.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 21, 2019
    Assignee: University of Rochester
    Inventor: Rudi Fasan
  • Patent number: 10288601
    Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: May 14, 2019
    Assignee: Phylogica Limited
    Inventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
  • Patent number: 10287338
    Abstract: Compositions of recombinant FVIII protein comprising point mutations. Methods for using recombinant FVIII to activate FX and FIXa in cells and treat diseases mediated by the degradation of FVIII are described.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: May 14, 2019
    Inventor: Miran Nersissian
  • Patent number: 10280206
    Abstract: Methods and systems are provided herein for on-line preparation of a sample for mass spectrometry. In accordance with various aspects of applicant's teachings, the methods and systems can provide for the reduction of a polypeptide, for example, on a liquid chromatography column and can reduce or eliminate the need to incubate the reducing agent with the polypeptide and/or expose the reduced polypeptide to an alkylating agent.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: May 7, 2019
    Assignee: DH Technologies Development Pte. Ltd.
    Inventor: Yves Le Blanc
  • Patent number: 10279017
    Abstract: A composition comprising as components a polypeptide IMPI? (including wild type) and/or a polypeptide IMPI?-fusion and at least one antibiotic compound, in particular an aminoglycoside antibiotic, and/or at least one bactericidal compound, wherein the polypeptides, the at least one antibiotic and the at least one bactericidal compound is present in the composition in concentrations which exhibit in combination a synergistic effect against resistant bacteria.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: May 7, 2019
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.
    Inventors: Mark Salzig, Andreas Vilcinskas, Rainer Fischer
  • Patent number: 10272130
    Abstract: The disclosure relates to compositions, methods and systems for treating cellular oxidative stress in a user. A composition of the disclosure includes an effective amount of reduced glutathione for reducing oxidative stress in the user and a deoxygenated water solvent. The composition is encapsulated in a phospholipid liposome structure and packaged and stored in an airless dispenser configured to maintain an anaerobic environment.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 30, 2019
    Inventors: Stephen N. Pitcher, Danny Clinton Purser
  • Patent number: 10273279
    Abstract: The present invention provides novel PAR1 derived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR1 and promoting PAR1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: April 30, 2019
    Assignee: The Scripps Research Institute
    Inventors: Laurent O. Mosnier, John H. Griffin
  • Patent number: 10265409
    Abstract: A macromolecule includes i) a dendrimer with a core and at least one generation of lysine residue building units, the outermost generation of building units having surface amino groups, ii) a first terminal group covalently attached to a first surface amino group of a building unit, which includes a residue of docetaxel (DTX), and iii) a second terminal group covalently attached to a second surface amino group of a building unit, which includes a pharmacokinetic modifying agent. The pharmacokinetic modifying agent can be a polyethylene glycol (PEG). The first terminal group can be covalently attached to the surface amino group of the dendrimer through a diacid linker. The diacid linker can include a 2,2?-thiodiacetic acid residue. The diacid linker can form an ester bond with a hydroxyl group of the DTX and an amide bond with the surface amino group. A pharmaceutically acceptable salt of the macromolecule can be prepared.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: April 23, 2019
    Assignee: STARPHARMA PTY LTD
    Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
  • Patent number: 10258717
    Abstract: The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: April 16, 2019
    Inventors: Gary Lee Bowlin, Isaac Anthony Rodriguez, Brenton Walter Burger
  • Patent number: 10258675
    Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: April 16, 2019
    Assignees: ProThera Biologics, Inc., Women & Infants Hospital of Rhode Island
    Inventors: Yow-Pin Lim, Barbara Stonestreet
  • Patent number: 10253071
    Abstract: This disclosure relates to selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one more modified amino acids conjugated to a saccharide or polysaccharide. In certain embodiments, the disclosure relates to uses of the glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: April 9, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Richard D. Cummings, Elliot L. Chaikof, Venkata R. Krishnamurthy, Mohammed Sardar
  • Patent number: 10253090
    Abstract: Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 9, 2019
    Assignee: Avicenna Nutraceutical, LLC
    Inventors: Ali Elnajjar, Ali Mourad, Mark Ernst Brandt, Christopher Lippelt
  • Patent number: 10251930
    Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: April 9, 2019
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, James V. Winkler
  • Patent number: 10253067
    Abstract: Methods for treating liquid cancer, determined to lack a p53 deactivation mutation, in a subject are provided. Also provided are peptidomimetic macrocycles for use in treatment of a liquid cancer, determined to lack a p53 deactivation mutation, in a subject.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 9, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Hubert Chen, David Allen Annis, Yong Chang, Manuel Aivado, Karen Olson, Chris Viau
  • Patent number: 10253066
    Abstract: The present invention relates to a process for the purification of Carfilzomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt %.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: April 9, 2019
    Assignee: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Maneesh Kumar Pandey, Raj Narayan Tiwari, Sarbjot Singh Sokhi, Govind Singh, Saswata Lahiri, Walter Cabri
  • Patent number: 10253064
    Abstract: The present invention provides a method for purifying an intended substance, a kit for purifying the intended substance, and a silicon oxide-binding tag for use in the method and the kit. In the present invention, a complex of a silicon oxide-binding tag and a substance is caused to specifically bind to silicon oxide in a solution for binding, to which solution no salt is added, and binding between the silicon oxide-binding tag and the silicon oxide is broken with use of arginine.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 9, 2019
    Assignee: Hiroshima University
    Inventors: Akio Kuroda, Takeshi Ikeda, Hisakage Funabashi
  • Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen